contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vistin-pharma-asa-third-quarter-and-ytd-2025-financial-results

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vistin Pharma is a Norwegian pharmaceutical company. The company conducts research and development and further production of pharmaceutical substances (API), mainly the substances metformin, codeine phosphate and pholcodine. The substances are mainly used in the treatment of diabetes. The company operates on a global level, with the largest presence in the Nordic market. Vistin Pharma was founded in 2015 and is headquartered in Oslo.

Vistin Pharma

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025...

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affected by higher sales volume, offset by lower global metformin prices compared to same quarter last year. EBITDA for first three months of 2025 ended at MNOK 89 compared to MNOK 77 YTD 2024, an increase of 16%. The net profit ended at MNOK 18.5 (16.6) for the third quarter of 2025. All time high production volume in the quarter with 1 600MT Metformin produced. The third quarter conference call, which will be held today, 31st of October at 8.30am (CET), will be available via webcast and audio through the following access points: Webcast: <a href="https://www.globenewswire.com/Tracker?data=pD4qkz4bj_5MfoM22Srnm7NcYwKJDHrVU9mp7gL3lql6UYr6IY78HgzDOKyfElX-N3whBiVKfsOq8JmQAxaJsvpeDkkrCh6rufU_ZNZWD9oHmOzIsqVzW66Kyo6LmG9ZUrbM1G3i4gePaw77jZhJ6ENkAPuP4pfHu8nXQS3gOgI=">https://edge.media-server.com/mmc/p/zojifvb6</a> Telephone conference (online registration): <a href="https://www.globenewswire.com/Tracker?data=pD4qkz4bj_5MfoM22SrnmyPflLqocNTlHX14boUTm4O_vOPL_q68_bbkbJNt8If1OidiAAFMwJ6TTfw4FurySlXNIbKQ5f8DLHNGbdgY6LZ52H5B8H1gzjQEzQpF3m8eu5LluvrF7b4R-RqxXG8ViX1SBZZQdYAPzeVimZtWR6mVTzkRKfj0Lahl3f9Viw_QbCGHcXkMthp4P8sUiYZpcQjllWv38XkAQS5rU0uyQm5vuIzvNtEajICouUY1RGDPeAoFMytfWbX-6ueZcXE93A==">https://register-conf.media-server.com/register/BI4b6411bcd117427f8df81e59f7b2fd65</a> The conference call will be held in English. &nbsp;&nbsp; Please find the Q3 report and presentation enclosed. The report and webcast (recorded) will also be made available on <a href="https://www.globenewswire.com/Tracker?data=RX3IQStTUEagTrvw50gLc8HShlvRwj122sF7vub_pdXa8gH2G8knayKfSGYiA_VzpO8Mqxl09v5MT3oA_SBC_tu9---zLVJW23cRUHCiqic=">www.vistin.com</a>. ***** For further information, please contact: Alexander Karlsen CFO +47 97 05&nbsp;36 21 <a href="https://www.globenewswire.com/Tracker?data=4o9-Ht7QgXwSBwroBtrwR1mMf7WoPplDi3N8jUAF7dKkrX3Dms0o32hk6Elu1_5f41i2WBiZLv4bladABdg5vVBXgWR-oA0KbyHEYf_48b0NArPljKAglvExZd9PWjTR">alexander.karlsen@vistin.com</a> This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. &nbsp; Attachments<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/eadbd2b8-2f05-4049-a978-7ad7aa03cd9d">Vistin Pharma ASA Q3 report 2025</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/f2ea00d5-6a3d-4a7a-9c85-0dbe09113135">Vistin Pharma_Q3_25_presentation</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTEzNjA4NCM0MDIyNTcxOTEjMjAxODc1NA==" alt=""> <img src="https://ml-eu.globenewswire.com/media/MzA1YWNhOGYtNWVlMC00N2QwLTk2ZGItM2NmYWQxYjVhMDI3LTEwMzAzMjctMjAyNS0xMC0zMS1lbg==/tiny/Vistin-Pharma-ASA.png" alt="">